Digest Network Come funziona
Network
/
Società
Mo
Non verificato

Molecular Targeting Technologies, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

11 comunicati stampa

Guarda tutti i comunicati
22/09/2026
Mercato del lavoro
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
MTTI Awarded $3.17 Million NCI Grant to Advance ¹⁷⁷Lu-EBRGD Development for Non-Small Cell Lung Cancer
Fonte
Molecular Targeting Technologies, Inc.
Emittente
Business Wire
1.00
0
01/09/2026
Eventi
Industria
Oncologia
Salute
Sanità
Medicina nucleare
Farmaceutica
Biotecnologia
Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™
Fonte
Molecular Targeting Technologies, Inc.
Emittente
Business Wire
1.00
0
07/07/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Molecular Targeting Technologies Presents First Clinical Validation of the Evans Blue Platform, Demonstrating Up to 15-Day Tumor Retention Using Approximately 12.5% of the Radioactivity Required for Conventional PRRT
Fonte
Molecular Targeting Technologies, Inc.
Emittente
Business Wire
1.00
0
10/06/2026
Fiere
Eventi
Industria
Biotecnologia
Medicina nucleare
Salute
Oncologia
MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026
Fonte
Molecular Targeting Technologies, Inc.
Emittente
Business Wire
1.00
0
28/05/2026
Biotecnologia
Sanità
Salute
Medicina - Varie
Oncologia
Industria
Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026
Fonte
Molecular Targeting Technologies, Inc.
Emittente
Business Wire
1.00
0
14/10/2025
Oncologia
Associazioni/Professionisti
Salute
Legge/Diritto
Medicina nucleare
Farmaceutica
Biotecnologia
Industria
Molecular Targeting Technologies, Inc. Initiates Legal Action Over Unauthorized Use of Albumin-binding Evans blue Targeted Radiotherapeutic (EB-TRT)
Fonte
Molecular Targeting Technologies, Inc.
Emittente
Business Wire
1.00
0
10/10/2025
Associazioni/Professionisti
Salute
Legge/Diritto
Scienza
Sanità
Molecular Targeting Technologies, Inc. Initiates Legal Action Over Unauthorized Use of Albumin-binding Evans blue (EB) Targeted Radiotherapeutic (EB-TRT)
Fonte
Molecular Targeting Technologies, Inc.
Emittente
Business Wire
1.00
0
22/07/2025
Salute
Medicina - Varie
Sanità
Medicina nucleare
Farmaceutica
Biotecnologia
Mercato del lavoro
MTTI Announces Dr. Danielle Meyrick to Lead Medical Team
Fonte
Molecular Targeting Technologies, Inc.
Emittente
Business Wire
1.00
0
09/12/2024
Industria
Università
Biotecnologia
Scuola/Istruzione
Salute
Libri/Editoria
Medicina nucleare
Farmaceutica
Oncologia
Comunicazione
Medicina - Varie
MTTI 225Ac-EBTATE is Highly Effective Against Neuroendocrine Tumors
Fonte
Molecular Targeting Technologies, Inc.
Emittente
Business Wire
1.00
0
12/09/2024
Eventi
Industria
Scienza
Medicina nucleare
Biotecnologia
Farmaceutica
Oncologia
Salute
Attrezzature medico-sanitarie
MTTI Reports on Fast-Acting Sprayable Molecule to Visualize Tumors for Real-Time Fluorescence-Guided Cytoreductive Surgery
Fonte
Molecular Targeting Technologies, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0